These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32413837)

  • 1. AQP4-IgG may cause muscle damage in patients with neuromyelitis optica spectrum disorder.
    Zhang Y; Chen H; Shi Z; Du Q; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
    Mult Scler Relat Disord; 2020 Jul; 42():102126. PubMed ID: 32413837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum.
    Guo Y; Lennon VA; Popescu BF; Grouse CK; Topel J; Milone M; Lassmann H; Parisi JE; Pittock SJ; Stefoski D; Balabanov R; Lucchinetti CF
    JAMA Neurol; 2014 Aug; 71(8):1025-9. PubMed ID: 24911400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.
    Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP
    Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD.
    Carnero Contentti E; Delgado-García G; Criniti J; López PA; Pettinicchi JP; Cristiano E; Miguez J; Correa-Díaz EP; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Tkachuk V; Caride A; Rojas JI
    Front Immunol; 2021; 12():628024. PubMed ID: 33717149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
    J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder.
    Tradtrantip L; Yeaman MR; Verkman AS
    Sci Rep; 2021 Nov; 11(1):21962. PubMed ID: 34753987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders.
    Akaishi T; Takahashi T; Himori N; Fujihara K; Misu T; Abe M; Ishii T; Nakazawa T; Aoki M; Nakashima I
    J Neuroimmunol; 2020 Mar; 340():577168. PubMed ID: 31986374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
    Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
    Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders.
    Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP
    Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    Wang R; Sun D; Wang X; Shi Z; Kong L; Du Q; Zhang Y; Chen H; Luo W; Zhang N; Zhou H
    J Neurol; 2024 Jul; 271(7):4503-4512. PubMed ID: 38703259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    Baek SH; Kim B; Shin JY; Choi SJ; Ahn SH; Choi YS; Kim SM; Sung JJ
    J Neuroimmunol; 2021 Sep; 358():577637. PubMed ID: 34229205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.